CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced data that was presented at the C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary. “KVD900 is an oral, novel, potent and selective inhibitor of plasma kallikrein, a validated target in hereditary angioedema, or HAE,” said Andrew